Autolus(US:AUTL)2025-03-20 14:18AUCATZYL Launch and Expansion - Autolus' AUCATZYL received FDA approval on November 8, 2024, triggering a $30 million milestone payment from Blackstone[12] - As of March 19, 2025, 33 treatment centers are authorized for AUCATZYL, covering over 60% of the target patient population, with a goal to reach approximately 60 centers covering 90% by the end of 2025[12, 23] - Over 85% of total U S medical lives are covered for AUCATZYL[22] - The anticipated payor mix for AUCATZYL is approximately 60% commercial and 40% government/other[23] Obe-cel Development - The FELIX trial data for obe-cel was published in the New England Journal of Medicine in December 2024[12] - The FELIX trial showed an overall remission rate of 77% in all patients, 75% in morphological disease, 96% in measurable residual disease, and 71% in isolated extramedullary disease[13] - In the FELIX trial, the estimated 6- and 12-month overall survival rates were 80 3% and 61 1%, respectively, with a median OS of 15 6 months[19, 20] - Regulatory decisions from MHRA and EMA regarding obe-cel are expected in H2 2025[12] Financial Performance - Autolus' cash, cash equivalents, and marketable securities totaled $588 023 million for FY 2024, compared to $239 566 million for FY 2023[35] - Total revenue, net, for FY 2024 was $10 120 million, compared to $1 698 million for FY 2023[35] - The net loss for FY 2024 was $(220 844) million, compared to $(208 383) million for FY 2023[35]